Shared Decision-Making and Real-World Access to Genomic Testing

Dr. Shah describes using shared decision-making with anxious patients who want to do everything possible — walking them through their specific recurrence risk and letting them decide with that information, whether that means choosing chemotherapy or avoiding it. On accessibility, she notes Prosigna is still becoming more widely available compared with established assays like Oncotype DX and MammaPrint, but expects that to improve. She encourages patients and community oncologists to ask about ordering the test, closing by calling OPTIMA one of the most impactful de-escalation studies in breast cancer to date.